Scholarlink

Background <p>Alport syndrome (AS) is a hereditary progressive kidney disease caused by pathogenic variants in the <i>COL4A3</i>, <i>COL4A4</i>, and <i>COL4A5</i> genes. Aberrant pre-mRNA splicing represents a major disease mechanism in AS, and both synonymous and intronic variants can disrupt splice-site recognition or regulatory elements, leading to exon skipping or intron retention. However, the clinical interpretation of putative spliceogenic variants remains challenging, particularly when subtle splicing changes coexist with background alternative splicing.</p> Results <p>Fourteen synonymous and intronic variants in <i>COL4A3</i> and <i>COL4A4</i> were screened using in silico splicing prediction tools and subsequently functionally evaluated by minigene assays in HEK293T and HeLa cells. Thirteen variants exhibited aberrant splicing, most commonly as exon skipping, with variable effects on transcript structure and abundance. Several variants predominantly generated frameshift transcripts with premature termination codons, whereas others resulted in in-frame exon skipping or produced low-level aberrant transcripts comparable to wild-type splicing. By integrating quantitative splicing outcomes with population frequency data and predicted protein consequences, all variants were reclassified according to ACMG/AMP guidelines, resulting in four pathogenic, nine likely pathogenic, and one likely benign variant.</p> Conclusions <p>This study demonstrates that synonymous and intronic variants in <i>COL4A3</i> and <i>COL4A4</i> can exert pathogenic effects primarily through disruption of pre-mRNA splicing rather than through direct alteration of the coding sequence. Incorporation of quantitative functional splicing data into ACMG/AMP variant interpretation provides a robust framework for resolving variants of uncertain significance and improves the molecular diagnosis of AS.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Functional validation of spliceogenic COL4A3 and COL4A4 variants by minigene assays refines molecular diagnosis of Alport syndrome

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月27日

查看全文
  • Lina Wang,
  • Zhi Wang,
  • Yan Zhao,
  • Xuyan Liu,
  • Qiaomei Cui,
  • Shuimi Zhang,
  • Ran Zhang,
  • Leping Shao

摘要

Background

Alport syndrome (AS) is a hereditary progressive kidney disease caused by pathogenic variants in the COL4A3, COL4A4, and COL4A5 genes. Aberrant pre-mRNA splicing represents a major disease mechanism in AS, and both synonymous and intronic variants can disrupt splice-site recognition or regulatory elements, leading to exon skipping or intron retention. However, the clinical interpretation of putative spliceogenic variants remains challenging, particularly when subtle splicing changes coexist with background alternative splicing.

Results

Fourteen synonymous and intronic variants in COL4A3 and COL4A4 were screened using in silico splicing prediction tools and subsequently functionally evaluated by minigene assays in HEK293T and HeLa cells. Thirteen variants exhibited aberrant splicing, most commonly as exon skipping, with variable effects on transcript structure and abundance. Several variants predominantly generated frameshift transcripts with premature termination codons, whereas others resulted in in-frame exon skipping or produced low-level aberrant transcripts comparable to wild-type splicing. By integrating quantitative splicing outcomes with population frequency data and predicted protein consequences, all variants were reclassified according to ACMG/AMP guidelines, resulting in four pathogenic, nine likely pathogenic, and one likely benign variant.

Conclusions

This study demonstrates that synonymous and intronic variants in COL4A3 and COL4A4 can exert pathogenic effects primarily through disruption of pre-mRNA splicing rather than through direct alteration of the coding sequence. Incorporation of quantitative functional splicing data into ACMG/AMP variant interpretation provides a robust framework for resolving variants of uncertain significance and improves the molecular diagnosis of AS.